Testing Semaglutide for Treating Alcohol Use Disorder in Adults After Weight Loss Surgery

What this Trial Is About

Researchers are evaluating the feasibility and acceptability of using Semaglutide to treat Alcohol Use Disorder in adults with overweight or obesity who have undergone metabolic and bariatric surgery. The study also aims to examine changes in alcohol use disorder symptoms and weight. Previous research suggests Semaglutide may reduce alcohol cravings and drinking, but this has not been studied in individuals with a history of bariatric surgery who are at higher risk of alcohol misuse. Participants in the study are randomly assigned to one of two groups. Those in the Semaglutide group receive weekly injections starting with a 0.25 mg dose for the first month, increasing to 0.5 mg in the second month, and 1.0 mg in the third month. The treatment lasts three months in total. The control group is placed on a wait-list and receives no treatment during the initial three months but may be offered a behavioral intervention afterward. During the study, participants undergo assessments to measure changes in weight and alcohol use at baseline, during treatment at weeks 4, 8, and 12, and at a 6-month follow-up. Researchers track drinking frequency, amount, and heavy drinking days. Participants are also monitored for safety and adherence throughout the study, which lasts up to six months including follow-up.

Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)